Merck & Co. Inc. (MRK): Price and Financial Metrics


Merck & Co. Inc. (MRK): $88.39

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MRK POWR Grades

  • MRK scores best on the Quality dimension, with a Quality rank ahead of 90.21% of US stocks.
  • The strongest trend for MRK is in Stability, which has been heading down over the past 179 days.
  • MRK's current lowest rank is in the Momentum metric (where it is better than 11.93% of US stocks).

MRK Stock Summary

  • With a market capitalization of $218,166,060,251, MERCK & CO INC has a greater market value than 99.44% of US stocks.
  • MRK's went public 36.78 years ago, making it older than 93.22% of listed US stocks we're tracking.
  • Over the past twelve months, MRK has reported earnings growth of 166.21%, putting it ahead of 90.33% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MERCK & CO INC are PFE, NVS, NVO, ABBV, and AZN.
  • Visit MRK's SEC page to see the company's official filings. To visit the company's web site, go to www.merck.com.

MRK Valuation Summary

  • In comparison to the median Healthcare stock, MRK's price/sales ratio is 100% higher, now standing at 3.8.
  • MRK's price/earnings ratio has moved down 1 over the prior 243 months.

Below are key valuation metrics over time for MRK.

Stock Date P/S P/B P/E EV/EBIT
MRK 2022-09-23 3.8 5.1 13.3 13.1
MRK 2022-09-22 3.9 5.1 13.4 13.2
MRK 2022-09-21 3.7 5.0 12.9 12.8
MRK 2022-09-20 3.8 5.0 13.1 13.0
MRK 2022-09-19 3.8 5.1 13.2 13.1
MRK 2022-09-16 3.9 5.1 13.4 13.2

MRK Growth Metrics

    Its 4 year cash and equivalents growth rate is now at 13.97%.
  • The 3 year price growth rate now stands at 12.57%.
  • Its 5 year cash and equivalents growth rate is now at 13.97%.
MRK's revenue has moved up $15,909,000,000 over the prior 49 months.

The table below shows MRK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 57,169 18,891 16,579
2022-03-31 53,978 17,079 14,180
2021-12-31 48,704 14,109 13,049
2021-09-30 49,151 13,084 7,197
2021-06-30 48,548 10,460 5,571
2021-03-31 48,018 11,337 7,028

MRK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRK has a Quality Grade of B, ranking ahead of 77.57% of graded US stocks.
  • MRK's asset turnover comes in at 0.535 -- ranking 75th of 682 Pharmaceutical Products stocks.
  • XTNT, ACOR, and BDSI are the stocks whose asset turnover ratios are most correlated with MRK.

The table below shows MRK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.535 0.675 0.129
2021-03-31 0.529 0.670 0.158
2020-12-31 0.538 0.677 0.171
2020-09-30 0.542 0.712 0.276
2020-06-30 0.550 0.701 0.260
2020-03-31 0.571 0.701 0.256

MRK Price Target

For more insight on analysts targets of MRK, see our MRK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $93.38 Average Broker Recommendation 1.52 (Moderate Buy)

MRK Stock Price Chart Interactive Chart >

Price chart for MRK

MRK Price/Volume Stats

Current price $88.39 52-week high $95.72
Prev. close $88.39 52-week low $71.50
Day low $88.02 Volume 6,065,600
Day high $88.78 Avg. volume 10,923,540
50-day MA $88.13 Dividend yield 3.12%
200-day MA $85.25 Market Cap 223.92B

Merck & Co. Inc. (MRK) Company Bio


Merck & Co., Inc.d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891.(Source:Wikipedia)


MRK Latest News Stream


Event/Time News Detail
Loading, please wait...

MRK Latest Social Stream


Loading social stream, please wait...

View Full MRK Social Stream

Latest MRK News From Around the Web

Below are the latest news stories about MERCK & CO INC that investors may wish to consider to help them evaluate MRK as an investment opportunity.

With Merck & Co., Inc. (NYSE:MRK) It Looks Like You'll Get What You Pay For

There wouldn't be many who think Merck & Co., Inc.'s ( NYSE:MRK ) price-to-earnings (or "P/E") ratio of 13.1x is worth...

Yahoo | October 2, 2022

What This News Means for Merck

In combination with Roche's (OTC: RHHBY) bevacizumab (Avastin), Merck's (NYSE: MRK) oncology medicine -- co-owned with AstraZeneca (NASDAQ: AZN) and known as Lynparza -- received the nod from China's National Medical Products Administration (NMPA) to treat patients with a form of advanced ovarian cancer. What led the NMPA to green-light the treatment combo?

Yahoo | October 1, 2022

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merck & Company (MRK), AbbVie (ABBV) and Intercept Pharma (ICPT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merck & Company (MRK – Research Report), AbbVie (ABBV – Research Report) and Intercept Pharma (ICPT – Research Report). Merck & Company (MRK) In a report released today, Daina Graybosch from SVB Securities maintained a Buy rating on Merck & Company, with a price target of $110.00. The company's shares closed last Friday at $86.19. According to TipRanks.

Howard Kim on TipRanks | September 30, 2022

3 Undervalued Dow Stocks to Buy Before Wall Street Catches On

These 6 Dow stocks should do well over the long term.

Will Ashworth on InvestorPlace | September 30, 2022

U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit

RAHWAY, N.J., September 29, 2022--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Court of Appeals for the Federal Circuit ruled in favor of the company in a patent challenge brought by Mylan Pharmaceuticals, Inc. (now Viatris) related to sitagliptin dihydrogen phosphate, an active ingredient in JANUVIA® (sitagliptin), JANUMET® (sitagliptin and metformin hydrochloride) and JANUMET® XR (sitagliptin and metformin hydrochloride extended-release

Yahoo | September 29, 2022

Read More 'MRK' Stories Here

MRK Price Returns

1-mo 3.10%
3-mo -3.96%
6-mo 2.45%
1-year 13.43%
3-year 15.62%
5-year 60.29%
YTD 18.26%
2021 -2.91%
2020 -7.20%
2019 22.27%
2018 39.95%
2017 -1.49%

MRK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full MRK Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6421 seconds.